<DOC>
	<DOCNO>NCT01004874</DOCNO>
	<brief_summary>This phase II study combination radiation therapy , temozolomide Avastin follow Avastin , temozolomide , topotecan grade IV malignant glioma patient .</brief_summary>
	<brief_title>Avastin/Radiation ( XRT ) /Temozolomide ( Temodar ) Followed Avastin/Temodar/Topotecan Glioblastoma</brief_title>
	<detailed_description>The primary objective study use 6-month progression-free survival ass efficacy combination radiation therapy , temozolomide Avastin follow Avastin , temozolomide , topotecan treatment grade IV malignant glioma patient follow surgical resection . Secondary objective determine overall survival follow combination radiation therapy , temozolomide Avastin follow Avastin , temozolomide , topotecan describe toxicity radiation therapy , temozolomide Avastin follow Avastin , temozolomide , topotecan . The study survival toxicity endpoint . Patients treated standard radiation therapy daily temozolomide 6 half week radiation . Avastin administer every week begin minimum 28 day last major surgical procedure , open biopsy , significant traumatic injury . Following completion radiation therapy , patient MRI evidence disease progression , patient receive 12 cycle Avastin , temozolomide , topotecan ( begin minimum 14 day last radiation treatment ) . Subjects identify investigator patient newly diagnose grade 4 malignant glioma ( glioblastoma multiforme gliosarcoma ) , within 6 week last major surgical procedure , craniotomy , open biopsy , stereotactic biopsy . Fifty ( 50 ) patient initially accrue study overall efficacy treatment regimen assess . Analyses conduct within subgroup define methylation status . Early side effect radiation may start radiation include hair loss , scalp redness , inflammation ear canal , fatigue . There small chance long-term effect radiation , occur month year completion . These may include worsen mental function , hearing , vision , strength coordination . In initial Phase I II clinical trial , four potential Avastin-associated safety signal identify : hypertension , proteinuria , thromboembolic event , hemorrhage . Temozolomide well tolerate adult child common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , hepatotoxicity . With topotecan , reversible myelosuppression leukopenia thrombocytopenia dose limit . Nausea vomiting , well diarrhea alopecia , frequent . Moderate fatigue , transient elevation hepatic transaminase level , stomatitis , anemia , fever , mucositis , flu-like symptom , rash report .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients must histologically confirm diagnosis WHO grade IV primary malignant glioma ( glioblastoma multiforme gliosarcoma ) . Patients within 6 week last major surgical procedure . Age &gt; = 18 year . An interval least 2 week &gt; 6 week prior major surgical procedure study enrollment . No prior radiotherapy chemotherapy brain tumor Karnofsky &gt; = 60 % . Hemoglobin ≥ 9.0 g/dl , absolute neutrophil count ( ANC ) ≥ 1,500 cells/microliter , platelet ≥ 125,000 cells/microliter . Serum creatinine ≤ 1.5 mg/dl , serum glutamic oxaloacetic transaminase ( SGOT ) bilirubin ≤ 1.5 time upper limit normal . Signed informed consent approve Institutional Review Board If sexually active , patient must agree use appropriate contraceptive measure duration study 6 month afterwards state informed consent . Pregnancy breast feed . Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid . Active infection require IV antibiotic . Prior treatment radiotherapy chemotherapy brain tumor , irrespective grade tumor . Evidence &gt; grade 1 central nervous system ( CNS ) hemorrhage baseline MRI CT scan . Avastinspecific Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior study enrollment History hemoptysis ( ≥ ½ teaspoon bright red blood per episode ) within 1 month prior study enrollment Evidence bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation within 6 month prior study enrollment Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screening demonstrate either urine protein : creatinine ( UPC ) ratio ≥ 1.0 screening OR urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Known hypersensitivity component Avastin Pregnant ( positive pregnancy test ) lactation . Use effective mean contraception ( men woman ) subject childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>malignant glioma</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Pro00019960</keyword>
	<keyword>Vredenburgh</keyword>
	<keyword>Duke</keyword>
</DOC>